IL17B

Across TCGA pan-cancer cohorts, IL17B RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of IL17B’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where IL17B RNA is repressed in tumor relative to normal tissue. In most cancer types IL17B is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

BLCA, KICH, and KIRP are the cancer types where IL17B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IL17B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−1.100	<.001	8	view →
KICH	Female	All	−0.835	<.001	8	view →
KIRP	Male	All	−0.568	<.001	7	view →
BRCA	Female	II,III,IV	−2.346	<.001	6	view →
UCEC	All	All	−0.981	<.001	6	view →
LIHC	Female	All	+0.200	<.001	5	view →
COAD	Male	II,III,IV	−0.655	<.001	4	view →
STAD	All	All	−0.414	.020	4	view →
PRAD	All	All	−0.578	<.001	2	view →
CHOL	All	All	+0.253	.005	2	view →
READ	Female	All	−0.754	.039	1	view →
LUSC	Male	III,IV	−0.565	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

IL17B–BLCA

Open the BLCA breakdown →